TYMJ-01

TYMJ-01 (500 nM; 3-48 h) enables real-time visualization of eEF2K degradation in immobilized MDA-MB-231 cells. Its fluorescence intensity decreases with increasing incubation duration from 3 to 48 h, and it colocalizes with nuclear eEF2K^[1].
TYMJ-01 (10 μM; 1-48 h) enables real-time visualization of eEF2K degradation in live MDA-MB-231 cells. Its fluorescence intensity peaks at 6 h and then decreases, with no associated cell damage^[1].
TYMJ-01 (500 nM; 24 h) exhibits extremely low single-agent cytotoxicity, but it significantly enhances the anti-tumor activity of Paclitaxel in MDA-MB-231 cells^[1].
TYMJ-01 (0.2-1.0 μM; 24 h) inhibits the proliferation of MDA-MB-231 cells^[1].
TYMJ-01 (0.2-1.0 μM; 48 h) induces G1-phase cell cycle arrest in MDA-MB-231 cells by downregulating key cell cycle regulators^[1].
TYMJ-01 (200 nM; 48 h) inhibits the migration of MDA-MB-231 cells by downregulating key migration-related regulatory factors^[1].
TYMJ-01 (4.12-1000 nM; 24 h) downregulates the expression of proliferation-, survival- and migration-related proteins c-Myc, Bcl-2 and N-cadherin in a dose-dependent manner in MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.